Trial Profile

TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 10 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atorvastatin (Primary)
Indications Cardiovascular disorders
Focus Therapeutic Use
Acronyms TRACE-RA; TRACE-RA-Biobank; TRACE-RA-DAS

Most Recent Events

13 Jun 2015 The trial had been discontinued according to the abstract presented at 16th Annual Congress of the European League Against Rheumatism.
13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism (n = 2986).
20 Mar 2015 Accrual to date 60% reported by United Kingdom Clinical Research Network record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com